Graphite Bio, Inc. (GRPH)
Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases.
Our next-generation gene editing platform allows us to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations.
We believe our approach could enable broad applications to transform human health, including directly correcting mutations, engineering cells to permanently deliver therapeutic proteins, and precisely engineering effector cells to treat or cure a wide range of serious genetic and other diseases, including cancer, autoimmune and neurodegenerative diseases.
Our lead product candidate GPH101 is a highly differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression.
We have received clearance of our Investigational New Drug (IND) and we intend to enroll the first patient in a Phase 1/2 clinical trial of GPH101 in the second half of 2021, with initial proof-of-concept data expected by the end of 2022.
We are also advancing our research programs and pipeline of potentially one-time curative therapies and intend to file an IND for a second program by mid 2023.
|IPO Date||Jun 25, 2021|
|CEO||Josh Lehrer, M.D.|
279 East Grand Avenue, Suite 430
South San Francisco, CA 94080
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Joshua Lehrer-Graiwer FACC, M.D.||President, Chief Executive Officer and Director|
|Dr. Matthew Porteus||Academic Founder and Director|
|Dr. Maria Grazia Roncarolo M.D., Ph.D.||Academic Founder|
|Philip P. Gutry||Chief Business Officer, Head of Finance and Investor Relations|
|Katherine Vega Stultz||Chief Operating Officer|
|Dr. Daniel Dever Ph.D.||Co-founder and Head of Translational Science|
|Jerry Cacia||Chief Technical Officer|
|Dr. Jane Grogan Ph.D.||Chief Scientific Officer|
|Julia Tran||Senior Vice President of People|